Skip to main content

IDH1 R132H peptide vaccine

A 20-mer peptide spanning the IDH1 R132H substitution, designed to raise a CD4+ T-cell response against a mutation the tumour cannot easily lose.

  • RegistryNCT02454634
  • PhasePhase 1
  • StatusCompleted
  • ConditionIDH1 R132H glioma
  • SponsorNCT Heidelberg
How the IDH1 peptide vaccine worksNCT02454634

The drug

What is being tested.

Most WHO grade 2 and 3 gliomas carry the same amino-acid change in isocitrate dehydrogenase 1: arginine 132 becomes histidine. That single substitution is both a diagnostic marker and a shared neoantigen — a mutant peptide the immune system can, in principle, see.

The vaccine is not a whole-cell product and not a personalized construct. It is one synthetic 20-mer peptide that spans the R132H mutation, given with an immune adjuvant. The aim is to present that peptide on MHC class II and recruit mutation-specific helper T cells.

Because R132H is an early, truncal event, every tumour cell is expected to keep it. That is the scientific bet: a target the glioma cannot shed without becoming a different disease.

The study

How the trial runs.

NOA-16 was a first-in-human study of the IDH1 R132H peptide vaccine in patients with IDH1-mutant gliomas. It asked whether the construct was safe, whether it induced mutation-specific T cells, and whether those cells could be found in blood and in tumour.

The published readout is immunological rather than a survival claim. Patients mounted IDH1-specific immune responses, and the work sits behind later, larger vaccine efforts in the same mutation.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • IDH1 R132H-mutant glioma, as used in the original protocol
  • Adequate performance status and organ function
  • No medical reason to avoid peptide vaccination or the chosen adjuvant

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.